Max Healthcare Institute Limited has received a significant relief in the form of a GST rectification order that withdraws the entire demand of ₹55,20,45,266 raised against the company. The rectification order was issued on April 21, 2026, by the Office of the GST Officer, Ward 96, Zone 9, Department of Trade and Taxes, New Delhi, and was received by the company on the same day at 12:27 PM IST.

GST Demand Withdrawal Details

The rectification order represents a complete reversal of the earlier GST demand that was raised against Max Healthcare Institute. The company has provided detailed disclosure under Regulation 30 of the SEBI Listing Obligations and Disclosure Requirements Regulations, 2015.

Background and Resolution

This development follows the company's earlier intimation dated December 30, 2025, wherein Max Healthcare Institute had informed about receiving an order from the Office of the GST Officer alleging excess availment of Input Tax Credit. The original order was issued by Ward-92&96, Department of Trade and Taxes, GNCT of Delhi.

Upon due consideration of the submissions made by the company, the GST authority accepted the rectification application filed by Max Healthcare Institute. The authority's decision to withdraw the entire demand indicates that the company's submissions were found to be satisfactory and compliant with GST regulations.

Regulatory Compliance

The company has fulfilled its disclosure obligations by informing both the National Stock Exchange of India Limited and BSE Limited about this development. The disclosure has also been hosted on the company's website at www.maxhealthcare.in as part of its transparency commitments.

The rectification order represents a positive outcome for Max Healthcare Institute, eliminating a significant financial liability that was previously under dispute. The company's proactive approach in filing the rectification application and providing necessary submissions to the GST authorities has resulted in the complete withdrawal of the demand.

HSBC has reaffirmed its positive outlook on Max Healthcare Institute by maintaining a Buy rating with a target price of ₹1,125, citing several favorable factors expected to drive performance in Q4FY26.

Key Investment Highlights

The brokerage's optimistic stance is based on multiple growth drivers and operational improvements expected in the coming quarter. HSBC anticipates steady performance supported by fundamental business strengths and strategic expansion initiatives.

Expected Performance Drivers

HSBC has identified several key factors that are expected to contribute to Max Healthcare Institute's performance:

Business Outlook

The brokerage expects a pickup in elective procedures, which typically contribute significantly to hospital revenues and margins. This recovery in elective procedures is viewed as a positive indicator for the company's core business operations.

Expansion and Investment Strategy

HSBC notes that Max Healthcare Institute is continuing its capital expenditure-led expansion strategy. This ongoing investment in infrastructure and capacity building is seen as positioning the company for long-term growth, despite potential short-term margin pressures from new facilities.

Operational Performance

The brokerage highlights sustained healthy operating trends across the hospital business, indicating strong fundamental performance in the company's core operations. While new unit operations may create some margin drag, HSBC considers this impact to be manageable within the overall business context.